Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Appili Therapeutics Inc

Healthcare CA APLI

0.02CAD
0.00(0%)

Last update at 2026-06-03T13:30:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.010.04
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap2.57M
  • Volume14469
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-6.16005M
  • Revenue TTM0.21M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 0.21M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Income before tax -2.60586M -3.74105M -9.20662M -9.20662M -25.07984M
Minority interest - - - - -
Net income -2.62469M -3.78091M -9.24301M -9.24301M -25.11830M
Selling general administrative 2.85M 3.05M 4.44M 4.60M 4.56M
Selling and marketing expenses - 0.14M 0.19M - 0.71M
Gross profit 0.10M 0.81M 0.33M - 1.39M
Reconciled depreciation 0.01M 0.01M 0.00627M 0.00627M 0.01M
Ebit 0.35M -8.02320M -7.74593M - -23.52490M
Ebitda 0.36M -8.00954M -7.73967M -8.10427M -23.51226M
Depreciation and amortization 0.01M 0.01M 0.00627M - 0.01M
Non operating income net other - - - - -
Operating income -0.19084M -8.02320M -7.91428M -7.91428M -24.67848M
Other operating expenses 0.29M 8.85M 8.11M - 24.95M
Interest expense 3.50M 1.63M 1.10M 1.10M 1.55M
Tax provision 0.02M 0.07M 0.04M 0.04M 0.04M
Interest income 3.83M 0.02M 1.43M 1.43M 0.03M
Net interest income -3.50085M -1.61419M -1.06620M -1.06620M -1.52121M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.04M 0.04M - 0.04M
Total revenue 0.10M 0.83M 0.33M 0.33M 1.39M
Total operating expenses 0.29M 8.84M 8.11M 8.11M 24.95M
Cost of revenue - 0.01M 0.00627M - -
Total other income expense net -2.41502M 4.28M -0.36461M -0.36461M -0.40136M
Discontinued operations - - - - -
Net income from continuing ops -2.62469M -3.78091M -9.24301M -9.24301M -25.11830M
Net income applicable to common shares -2.62469M - -9.24301M -9.24301M -25.11830M
Preferred stock and other adjustments - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Total assets 3.03M 1.49M 3.13M 3.13M 8.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.19M 0.23M - 0.18M
Total liab 16.43M 12.42M 10.53M 10.53M 11.55M
Total stockholder equity -13.39734M -10.92478M -7.39698M -7.39698M -3.27054M
Deferred long term liab - - - - -
Other current liab - 0.08M 0.23M - 0.12M
Common stock 42.32M 42.32M 42.32M 42.32M 39.65M
Capital stock 42.32M 42.32M 42.32M 42.32M 39.65M
Retained earnings -70.53877M -69.09312M -65.31221M -56.13330M -56.06919M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M - - -
Cash 1.23M 0.09M 2.47M 2.47M 6.66M
Cash and equivalents - - - - -
Total current liabilities 15.69M 11.54M 2.98M 2.98M 6.67M
Current deferred revenue - 0.05M -0.18887M - -
Net debt 11.07M 8.09M 5.20M 5.20M -1.68617M
Short term debt 0.00000M 7.31M 0.11M 0.00000M 0.10M
Short long term debt 11.56M 7.31M 0.11M 0.11M 0.10M
Short long term debt total - 8.18M 7.67M - 4.98M
Other stockholder equity - 12.87M 6.41M - 13.15M
Property plant equipment 0.02M - 0.01M 0.01M 0.04M
Total current assets 3.01M 1.46M 3.12M 3.12M 8.24M
Long term investments - - - - -
Net tangible assets - - - - -3.27054M
Short term investments - - - - 0.00000M
Net receivables 1.50M 1.17M 0.42M 0.00000M 1.39M
Long term debt 0.74M 0.88M 7.55M 7.55M 4.88M
Inventory - - - - -
Accounts payable 4.11M 4.11M 2.82M 2.82M 6.46M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.98M 9.18M - 8.13M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -0.00000M -0.01461M - -0.04225M
Deferred long term asset charges - - - - -
Non current assets total 0.02M 0.03M 0.01M 0.01M 0.04M
Capital lease obligations - - - - -
Long term debt total 0.74M - 7.55M 7.55M 4.88M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-12-31 2022-03-31
Investments -0.00236M -0.02906M -0.00317M -0.00317M 5.06M
Change to liabilities - - - - 1.65M
Total cashflows from investing activities -0.00236M - -0.00318M -0.00318M 5.06M
Net borrowings 0.26M - - - 3.83M
Total cash from financing activities 0.19M 0.19M 5.91M 5.91M 9.56M
Change to operating activities - - - - 0.27M
Net income -2.62469M -3.78091M -9.24301M -9.24301M -25.11830M
Change in cash 1.13M -2.37139M -4.19897M -4.19897M -4.39808M
Begin period cash flow 0.09M 2.47M 6.66M 6.66M 11.06M
End period cash flow 1.23M 0.09M 2.47M 2.47M 6.66M
Total cash from operating activities 0.87M -2.53695M -10.09784M -10.09784M -19.08118M
Issuance of capital stock - 0.00000M 3.21M 3.21M 5.34M
Depreciation 0.01M 0.01M 0.00627M 0.00627M 0.01M
Other cashflows from investing activities 0.00000M - 0.00000M 0.00000M 5.06M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - 4.16M - -1.92446M
Change to account receivables -0.49754M -0.75255M 0.35M 0.35M 0.57M
Sale purchase of stock - - 4.50M 4.50M 7.04M
Other cashflows from financing activities -0.06450M -0.00901M 2.78M -1.00598M 8.39M
Change to netincome - - - - 3.54M
Capital expenditures 0.00236M 0.03M 0.00317M 0.00318M 0.00209M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.22619M 0.66M -3.23559M -3.23559M 2.49M
Stock based compensation 0.12M 0.19M 0.88M 0.88M 2.04M
Other non cash items 3.59M 1.35M 1.10M 1.10M 1.55M
Free cash flow 0.87M -2.56666M -10.10101M -10.10101M -19.08118M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APLI
Appili Therapeutics Inc		 - -% 0.02 - 2.38 12.44 1.40 71.81 37.42
EPRX
Eupraxia Pharmaceuticals Inc		 -0.38 4.11% 8.87 - - - 8.45 -3.8823
FRX
Fennec Pharmaceuticals Inc		 -1.04 7.56% 12.72 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -1.36 14.06% 8.31 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 0.02 1.28% 1.58 - 3.87 4263.36 9.74 4422.35 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics Inc

1344 Summer Street, Halifax, NS, Canada, B3H 0A8

Key Executives

Name Title Year Born
Dr. Donald D. Cilla Jr., M.B.A., Pharm.D., Pharmd CEO, Pres & Director NA
Mr. Kenneth G. Howling Acting Chief Financial Officer NA
Dr. Yoav Golan M.S., M.D., MS Chief Medical Officer 1962
Dr. Donald D. Cilla Jr., M.B.A., Pharmd CEO, President & Director NA
Mr. Kenneth G. Howling Chief Financial Officer NA
Dr. Gary S. Nabors Ph.D. Chief Development Officer NA
Dr. Carl Gelhaus Ph.D. Director of Non-Clinical Research NA
Mr. Arthur Baran Director of New Product Development NA
Jenna McNeil Corporate Affairs & Communications Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions